These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 938964)

  • 1. Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations.
    Britt BA; Endrenyi L; Peters PL; Kwong FH; Kadijevic L
    Can Anaesth Soc J; 1976 May; 23(3):263-84. PubMed ID: 938964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of creatinine phosphokinase in screening patients for malignant hyperpyrexia.
    Ellis FR; Clarke IM; Modgill M; Currie S; Harriman DG
    Br Med J; 1975 Aug; 3(5982):511-3. PubMed ID: 1164612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoenzymes of creatine phosphokinase in serum of families with malignant hyperpyrexia.
    Meltzer HY; Hassan SZ; Russo P; Cho HW
    Anesth Analg; 1976; 55(6):797-9. PubMed ID: 1033694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creatine phosphokinase (CPK) levels in pregnancy: a case report and a discussion of the value of CPK levels in the prediction of possible malignant hyperpyrexia.
    Isherwood DM; Ridley J; Wilson J
    Br J Obstet Gynaecol; 1975 Apr; 82(4):346-9. PubMed ID: 1125158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of serum creatine phosphokinase activity for the porcine malignant hyperthermia syndrome.
    Heffron JJ; Mitchell G
    Anesth Analg; 1975; 54(4):536-9. PubMed ID: 1170791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of susceptibility to malignant hyperpyrexia.
    Moulds RF; Denborough MA
    Br Med J; 1974 May; 2(5913):245-7. PubMed ID: 4827071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.
    Monnier N; Krivosic-Horber R; Payen JF; Kozak-Ribbens G; Nivoche Y; Adnet P; Reyford H; Lunardi J
    Anesthesiology; 2002 Nov; 97(5):1067-74. PubMed ID: 12411788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant hyperthermia: a possible new variant.
    Lee DS; Adams JP; Zimmerman JE
    Can Anaesth Soc J; 1985 May; 32(3 Pt 1):268-71. PubMed ID: 4005678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of pre-operative creatin phosphokinase (CPK) level--usefulness as a screening test for malignant hyperpyrexia (author's transl)].
    Morikawa S; Murata M; Murata H; Iwai S
    Masui; 1979 Feb; 28(2):187-96. PubMed ID: 423358
    [No Abstract]   [Full Text] [Related]  

  • 10. Markedly delayed postoperative malignant hyperthermia.
    Souliere CR; Weintraub SJ; Kirchner JC
    Arch Otolaryngol Head Neck Surg; 1986 May; 112(5):564-6. PubMed ID: 3954899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Masseter muscle rigidity and malignant hyperthermia susceptibility.
    Rosenberg H; Fletcher JE
    Anesth Analg; 1986 Feb; 65(2):161-4. PubMed ID: 3942303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia.
    Paasuke RT; Brownell AK
    JAMA; 1986 Feb; 255(6):769-71. PubMed ID: 3944979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: Serum creatine phosphokinase and malignant hyperpyrexia.
    Ryan DW; Appleyard TN
    Br Med J; 1976 Jan; 1(6001):96. PubMed ID: 1244960
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: Serum creatine phosphokinase and malignant hyperpyrexia.
    Ellis FR; Clarke IM; Modgill EM; Currie S; Harriman DG
    Br Med J; 1976 Mar; 1(6009):584. PubMed ID: 1260292
    [No Abstract]   [Full Text] [Related]  

  • 15. Malignant hyperpyrexia: Investigation of a family after a fatal case.
    Ryan DW; Appleyard TN
    Br J Anaesth; 1975 Sep; 47(9):1001-4. PubMed ID: 1191461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of malignant hyperthermia in Denmark and Sweden.
    Ording H; Ranklev E; Fletcher R
    Br J Anaesth; 1984 Nov; 56(11):1183-90. PubMed ID: 6487440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant hyperthermia.
    Bandschapp O; Girard T
    Swiss Med Wkly; 2012; 142():w13652. PubMed ID: 22851008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetics of malignant hyperthermia: evidence for heterogeneity.
    McPherson E; Taylor CA
    Am J Med Genet; 1982 Mar; 11(3):273-85. PubMed ID: 7081293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Malignant hyperthermia. Familial screening of CPK].
    Scarascia E; Magalini S; Proietti R; Pelosi G
    Minerva Anestesiol; 1976 Jun; 42(6):439-44. PubMed ID: 958641
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of creatinine phosphokinase screening as a predictor of malignant hyperthermia. A prospective study.
    Amaranath L; Lavin TJ; Trusso RA; Boutros AR
    Br J Anaesth; 1983 Jun; 55(6):531-3. PubMed ID: 6860521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.